Blocking PTH1R rescued TGFBR2 protein levels in osteoblasts and overcame enzalutamide resistance in a coculture system of prostate cancer and osteoblast cells, suggesting PTH1R as a novel target to overcome enzalutamide resistance in prostate cancer bone metastasis. Here, PTH1R is linked to prostate carcinoma.